Tazocin

Per 2 g/250 mg inj Piperacillin Na 2 g, tazobactam Na 250 mg. Per 4 g/500 mg inj Piperacillin Na 4 g, tazobactam Na 500 mg

Systemic &/or local bacterial infections caused by gm +ve & gm -ve aerobic & anaerobic organisms susceptible to piperacillin/tazobactam or piperacillin. Adult: Lower resp tract, intra-abdominal, skin & skin structure, gynecological including post-partum endometritis & pelvic inflammatory disease, bone & joint, polymicrobial & UTI. Febrile neutropenic infections in combination w/ aminoglycosides. Bacterial septicemia. Childn (≥2 yr): Febrile neutropenic in combination w/ aminoglycosides & intra-abdominal infections.

Slow IV infusion (eg, over 20-30 min). Adult & childn ≥12 yr 12 g piperacillin/1.5 g tazobactam in divided doses every 6 or 8 hr. Severe infections 18 g piperacillin/2.25 g tazobactam in divided doses daily. Febrile neutropenia Childn >50 kg Follow adult dose + appropriate dose of aminoglycoside. Normal renal function & <50 kg 80 mg piperacillin/10 mg tazobactam/kg every 6 hr + appropriate dose of aminoglycoside. Intra-abdominal infection Childn 2-12 yr & >40 kg w/ normal renal function Follow adult dose for a min of 5 days & max of 14 days duration; 2-12 yr & up to 40 kg w/ normal renal function 100 mg piperacillin/12.5 mg tazobactam/kg every 8 hr. Renal impairment CrCl 20-40 mL/min Max: 4 g/0.5 g every 8 hr. <20 mL/min Max: 4 g/0.5 g every 12 hr. Patients on hemodialysis 1 additional dose of 2 g/0.25 g should be administered following each dialysis period.

Hypersensitivity to piperacillin, tazobactam & to any β-lactams (including penicillins, cephalosporins) or β-lactamase inhibitors.

Previous hypersensitivity reactions to penicillins, cephalosporins, & other allergens. May cause severe cutaneous adverse reactions eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction w/ eosinophilia & systemic symptoms, & acute generalised exanthematous pustulosis. Antibiotic-induced pseudomembranous colitis. Discontinue if bleeding manifestations occur. Hypokalemia may occur in patients w/ low K reserves or those receiving concomitant medications that may lower K levels; periodic electrolyte determinations is advisable. Leukopenia & neutropenia may occur, especially during prolonged therapy; perform periodic assessment of hematopoietic function. Convulsions (seizures) may occur w/ high doses in patients w/ impaired renal function. Overgrowth of non-susceptible organisms, including fungi. Hepatic & renal impairment. Pregnancy & lactation.

Pseudomembranous colitis, candida infection; pancytopenia, agranulocytosis, neutropenia, hemolytic anemia, thrombocytopenia, anemia, leukopenia, thrombocytosis, eosinophilia; anaphylactoid shock/reaction, anaphylactic shock/reaction, hypersensitivity; hypokalemia; delirium, insomnia; seizure, headache; hypotension, phlebitis, thrombophlebitis, flushing; eosinophilic pneumonia, epistaxis; stomatitis, abdominal pain, vomiting, diarrhea, constipation, nausea, dyspepsia; hepatitis, jaundice; toxic epidermal necrolysis, Stevens-Johnson syndrome, drug reaction w/ eosinophilia & systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), dermatitis exfoliative, erythema multiforme, dermatitis bullous, rash, pruritus, urticaria, maculo-papular rash, purpura; arthralgia, myalgia; renal failure, tubulointerstitial nephritis; pyrexia, inj site reaction, chills; +ve Coombs' direct test; prolonged activated partial thromboplastin time, prothrombin time, bleeding time; decreased blood albumin, protein total, blood glucose; increased AST/ALT, blood alkaline phosphatase, blood bilirubin, γ-glutamyl transferase, blood creatinine/urea.

Heparin, oral anticoagulants & other drugs that may affect blood coagulation system, including thrombocyte function (perform appropriate coagulation tests more frequently & monitor regularly). Longer t_1/2 & lower renal clearance w/ probenecid. Increased incidence of acute kidney injury w/ vancomycin. May result in a false +ve reaction for glucose in urine using a copper-reduction method. +ve test results using the Bio-Rad Laboratories Platelia Aspergillus enzyme immunoassay (EIA) test in patients who were subsequently found to be free of Aspergillus infection. Cross-reactions w/ non-Aspergillus polysaccharides & polyfuranoses w/ Bio-Rad Laboratories Platelia Aspergillus EIA. Piperacillin: Prolonged neuromuscular blockade of vecuronium & other nondepolarizing muscle relaxants. May reduce the excretion of methotrexate.

Penicillins

J01CR05 - piperacillin and beta-lactamase inhibitor ; Belongs to the class of penicillin combinations, including beta-lactamase inhibitors. Used in the systemic treatment of infections.

Rx